Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. VINGE ADVISES ANICURA IN CONJUNCTION WITH THE ACQUISITION OF VETERINÄRMOTTAGNING I NÄSUM
Mandate

VINGE ADVISES ANICURA IN CONJUNCTION WITH THE ACQUISITION OF VETERINÄRMOTTAGNING I NÄSUM

December 03, 2014

Vinge has advised AniCura in conjunction with its acquisition of the veterinary clinics, Veterinärmottagning i Näsum and its branch in Bromölla, which is located close to Kristianstad. The merger entails that the veterinary clinics have thereby gained a strong partner to assist in their future expansion efforts and at the same time AniCura has strengthened its position in southern Sweden. AniCura is a leader in advanced veterinary care for dogs, cats and other companion animals. The company was founded on the notion of combining resources to provide better veterinary care. Established in 2011, AniCura is the first merger of companion animal hospitals in the Nordic region, and is currently the only Nordic veterinary care group exclusively focused on companion animals.

Vinge’s team consisted of partner Jonas Bergström together with, among others, associates Gustav Jönsson and Ulrika Andersson.

Related

Vinge has advised Oncopeptides in connection with its rights issue

 Vinge has advised Oncopeptides AB (publ) in connection with a fully guaranteed rights issue which will provide Oncopeptides with proceeds of approximately SEK 150 million before deduction of transaction costs.
August 28, 2025

Vinge advises Main Capital and Unik in connection with the acquisition of LEB System Aktiebolag

 Vinge has advised Unik International ApS (“Unik”), a Danish Housing and Property Management software provider, in connection with the acquisition of LEB System Aktiebolag. The synergistic acquisition is expected to complement and expand Unik’s offering and has a strong strategic fit with Unik and is in line with the company’s internationalization strategy in the Nordic Property Management software market.
August 28, 2025

Vinge has advised Xspray Pharma in connection with its rights issue and debt refinancing

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 130 million before transaction costs, with an over-allotment issue of approximately SEK 20 million, and refinancing of an existing loan.
August 28, 2025